NCT06982274View on ClinicalTrials.gov

Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

October 20, 2023

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2029

Conditions
Acute Promyelocytic Leukemia (APL)
Interventions
DRUG

Realgar-Indigo Naturalis Formulation

Oral Arsenic (Realgar-Indigo Naturalis Formulation) plus ATRA for low-intermediate risk APL pts, combined with daunorubicin for high-risk during induction

Trial Locations (1)

01246000

RECRUITING

Instituto do Cancer do Estado de Sao Paulo, São Paulo

All Listed Sponsors
collaborator

American Society of Hematology

OTHER

lead

Instituto do Cancer do Estado de São Paulo

OTHER